Recent advances in neuroprotection for treating traumatic brain injury
Author:
- 16 October 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 15 (11) , 1371-1381
Abstract
The fact that traumatic brain injury is the leading cause of death and disability in the most active population (< 45 years of age) of industrialised countries underscores the need for intensified efforts to define and implement effective neuroprotective strategies. However, despite progressively growing knowledge on the mechanisms involved in the pathobiology of traumatic brain injury and promising preclinical findings, most of the neuroprotection trials have failed to deliver the expected level of beneficial effects. Some of the possible reasons underlying the lack of success of these clinical trials are addressed in this review, which describes some of the most promising and/or controversial ongoing clinical trials from their pathophysiological basis. In addition, new neurobiological findings and their consequence for novel neuroprotective approaches are discussed.Keywords
This publication has 79 references indexed in Scilit:
- Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trialThe Lancet Neurology, 2006
- Animal models of head traumaNeuroRX, 2005
- Magnesium Sulfate in Aneurysmal Subarachnoid HemorrhageStroke, 2005
- PlaceboThe Lancet, 2005
- Magnesium Neuroprotection is Limited in Humans With Acute Brain InjuryNeurocritical Care, 2005
- Mild Postischemic Hypothermia Prolongs the Time Window for Gene Therapy by Inhibiting Cytochrome c ReleaseStroke, 2004
- Critical appraisal of neuroprotection trials in head injury: What have we learned?NeuroRX, 2004
- Clinical Trials in Traumatic Brain InjuryAnnals of the New York Academy of Sciences, 1997
- Effects of Pegorgotein on Neurologic Outcome of Patients With Severe Head InjuryJAMA, 1996
- Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the ratBrain Research, 1995